
|Videos|November 9, 2017
Improved Understanding of JAK2 Inhibition in Polycythemia Vera
Author(s)John O. Mascarenhas, MD
John O. Mascarenhas, MD, associate professor of medicine, Icahn School of Medicine at Mount Sinai Hospital, discusses the optimal use of ruxolitinib (Jakafi) and the improved understanding of JAK2 inhibition of polycythemia vera.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















